We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current FULC market cap is 224.38M. The company's latest EPS is USD -1.8045 and P/E is -2.30.
| Quarter End | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.18M | 871k | 0 | 80M | 0 |
| Operating Income | -55.23M | -27.99M | -29.83M | 52.49M | -25.13M |
| Net Income | -48.56M | -24.76M | -26.87M | 55.41M | -21.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 8.82M | 19.16M | 6.34M | 2.81M |
| Operating Income | -84.22M | -71.61M | -81.05M | -112.56M | -110.66M |
| Net Income | -89.81M | -70.82M | -80.85M | -109.87M | -97.34M |
| Quarter End | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 300.33M | 257.69M | 232.59M | 294.26M | 279.01M |
| Total Liabilities | 24.9M | 22.5M | 19M | 20.47M | 21.72M |
| Total Equity | 275.43M | 235.19M | 213.59M | 273.79M | 257.29M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 110.44M | 129.58M | 235M | 226.69M | 257.69M |
| Total Liabilities | 23.29M | 34.4M | 23.46M | 27.74M | 22.5M |
| Total Equity | 87.15M | 95.18M | 211.54M | 198.94M | 235.19M |
| Quarter End | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -44.9M | -90.97M | -25.28M | 33.62M | 14.54M |
| Investing | -74.07M | -36.69M | 38.13M | 25.62M | 29.97M |
| Financing | 117.84M | 118.12M | 1.65M | 2.03M | 2.66M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -39.48M | -53.66M | -78.48M | -97.05M | -90.97M |
| Investing | -944k | -57.14M | -129.67M | 12.41M | -36.69M |
| Financing | 64.34M | 71.13M | 186.51M | 84.32M | 118.12M |
| Market Cap | 224.38M |
| Price to Earnings Ratio | -2.30 |
| Price to Sales Ratio | 79.81 |
| Price to Cash Ratio | 8.76 |
| Price to Book Ratio | 0.95 |
| Dividend Yield | - |
| Shares Outstanding | 53.94M |
| Average Volume (1 week) | 564.79k |
| Average Volume (1 Month) | 660.76k |
| 52 Week Change | -38.73% |
| 52 Week High | 13.70 |
| 52 Week Low | 2.86 |
| Spread (Intraday) | 0.88 (17.64%) |
| Company Name | Fulcrum Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.fulcrumtx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
